Travere (TVTX) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Travere Therapeutics reported a revenue of $129.69 million for the quarter ended December 2025, reflecting a year-over-year increase of 73.4% [1] - The earnings per share (EPS) was $0.03, a significant improvement from -$0.73 in the same quarter last year, with an EPS surprise of +16.73% [1] - The reported revenue was below the Zacks Consensus Estimate of $142.46 million, resulting in a revenue surprise of -8.97% [1] Revenue Breakdown - Revenue from Tiopronin products / Thiola was $23.27 million, slightly above the estimated $21.9 million, but a decrease of 2.6% compared to the previous year [4] - Total net product sales reached $126.61 million, exceeding the average estimate of $125.35 million, marking a year-over-year increase of 72.2% [4] - Revenue from FILSPARI was $103.34 million, slightly above the estimated $103.05 million, representing a substantial increase of 108.2% year-over-year [4] - License and collaboration revenue was reported at $3.08 million, significantly lower than the average estimate of $15.33 million, but still showing a year-over-year increase of 148.3% [4] Stock Performance - Over the past month, shares of Travere have returned -1.4%, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]